The PPARγ agonist stabilized the altered hepatic circadian-clock and related gene expression, implying that the peripheral circadian-clock system, especially in the liver, is an attractive therapeutic candidate for treating the metabolic syndrome. The gene discussed is PPARG; the disease is metabolic syndrome.